SEC Comment Letter for Global Clean Energy Holdings, Inc. (GCEH) (CIK 0000748790) — Jun 6, 2022

Global Clean Energy Holdings, Inc. (GCEH) (CIK 0000748790)
Date: June 6, 2022 · CIK: 0000748790 · Accession: 0000000000-22-006085

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-265332

Date

June 6, 2022

Author

Not clearly detected

Form

UPLOAD

Company

Global Clean Energy Holdings, Inc. (GCEH) (CIK 0000748790)

Letter

United States securities and exchange commission logo June 6, 2022 Richard Palmer Chief Executive Officer Global Clean Energy Holdings, Inc. 2790 Skypark Drive Suite 105 Torrance, California 90505 Re:Global Clean Energy Holdings, Inc. Registration Statement on Form S-3 Filed June 1, 2022 File No. 333-265332 Dear Mr. Palmer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Michael Davis at 202-551-4385 or Celeste Murphy at 202-551-3257 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Calvin Cheng

Show Raw Text

United States securities and exchange commission logo
June 6, 2022
Richard Palmer
Chief Executive Officer
Global Clean Energy Holdings, Inc.
2790 Skypark Drive
Suite 105
Torrance, California 90505
Re:Global Clean Energy Holdings, Inc.
Registration Statement on Form S-3
Filed June 1, 2022
File No. 333-265332
Dear Mr. Palmer:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Michael Davis at 202-551-4385 or Celeste Murphy at 202-551-3257 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Calvin Cheng

SecProbe.io